Ruthenium Dihydroxybipyridine Complexes are Tumor Activated Prodrugs Due to Low pH and Blue Light Induced Ligand Release

Ruthenium drugs are potent anti-cancer agents, but inducing drug selectivity and enhancing their modest activity remain challenging. Slow Ru ligand loss limits the formation of free sites and subsequent binding to DNA base pairs. Herein, we designed a ligand that rapidly dissociates upon irradiation...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hufziger, Kyle T., Thowfeik, Fathima Shazna, Charboneau, David J., Nieto, Ismael, Dougherty, William G., Kassel, W. Scott, Dudley, Timothy J., Merino, Edward J., Papish, Elizabeth T., Paul, Jared J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3882005/
https://ncbi.nlm.nih.gov/pubmed/24184694
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jinorgbio.2013.10.008
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados